SynuCa Therapeutics is developing small molecule therapeutics to address the root cause of Parkinson's Disease by restoring neuronal calcium homeostasis. Their first-in-class approach targets SERCA calcium transporters to halt or reverse neurodegeneration.
Funding
$526.1K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's Disease is characterized by neuronal calcium imbalances stemming from pathological alpha-synuclein aggregation. Current therapeutic strategies primarily focus on symptomatic relief rather than addressing the underlying molecular pathology.
Solution
SynuCa Therapeutics is developing disease-modifying small molecules that target SERCA calcium transporters to restore neuronal calcium homeostasis. By salvaging the root cause of Parkinson's Disease, these first-in-class therapeutics aim to halt or reverse neurodegeneration. Our approach leverages established research in P-type ATPases and neuroscience to create novel treatments for Parkinson's Disease and related neurodegenerative disorders.
Target Audience
The primary target audience includes patients diagnosed with Parkinson's Disease and the neurologists and researchers focused on neurodegenerative disease therapeutics.
Features
- Small molecule therapeutics designed to modulate SERCA calcium transporters.
- Mechanism of action focuses on correcting neuronal calcium dysregulation associated with alpha-synuclein pathology.
- First-in-class approach targeting a fundamental disease mechanism in Parkinson's Disease.
- Development pipeline based on foundational research from Aarhus University.